Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.10 -0.15 (-4.77%)
As of: Oct 22, 2026 · 3:57 PM EDT

Apimeds Pharmaceuticals US (APUS) Return on Assets [ROA] (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) posted Return on Assets [ROA] of -14.51% for Q2 2026, up 54.31 percentage points from -68.81% a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Apimeds Pharmaceuticals US's Return on Assets [ROA] came in at -14.72%, up 624.16 percentage points from FY2024.

  • In prior years, Apimeds Pharmaceuticals US's Return on Assets [ROA] was -638.88% in FY2024.
  • Quarterly Return on Assets [ROA] has run from a low of -1096.06% in Q1 2025 to a high of -13.94% in Q4 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 8.08%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 4.65%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 2.45%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 10.60%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 9.10%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 9.29%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -6.13%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 2.14%
10 Apimeds Pharmaceuticals US 5.39 Mn -14.24 Mn - -14.51%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.51%
Dec 31, 2025 -13.94%
Sep 30, 2025 -52.33%
Jun 30, 2025 -68.81%
Mar 31, 2025 -1,096.06%
API Access

Apimeds Pharmaceuticals US Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=APUS&period=max&api_key=YOUR_API_KEY